Observational studyMolecular psychiatry2023
Distinct profiles of anhedonia and reward processing and their prospective associations with quality of life among individuals with mood disorders.
Observational study in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01976975 (Multi Level Analysis of Positive Valence Systems Across Mood Disorders), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi Level Analysis of Positive Valence Systems Across Mood Disorders
Who cites it
37 citing papers in PubMed, 45 citations in OpenAlex.
- Quality of life in older adults is enhanced by piano practice: Results from a randomized controlled trial.Annals of the New York Academy of Sciences · 2025Trial
- Selective KOR antagonist alters functional patch sizes in individualized brain system: results from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation.Molecular psychiatry · 2025Trial
- Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials.Advances in therapy · 2025Trial
- A Phase 2 Randomized Trial of NBI-1065846 (TAK-041) in Patients With Anhedonia Associated With Major Depressive Disorder: Results of the TERPSIS Study.Journal of clinical psychopharmacologyTrial
- Research agenda to advance anhedonia assessment, understanding and treatment: an ECNP-GALENOS expert meeting report.BMJ mental health · 2026Review
- Probing biomarkers and clinical utility of reward learning across species using the Probabilistic Reward Task: 20 years of findings.Nature. Mental health · 2026Article
- Blunted anticipation, but not consummation, of food rewards in depression.Cell reports. Medicine · 2026Article
- On the relationships between apathy, depression and anhedonia.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Decisional reference point pathology: A cognitive mechanism for and a correlate of major depressive disorder in humans.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- TLR7-induced murine inflammation results in a global neuroinflammatory response driving neural circuit-specific transcriptomic changes.Scientific reports · 2026Article
- Anticipatory pleasure as a key hedonic component in classifying major depressive disorder: multidimensional behavioral evidence from majority vote algorithm.BMC psychiatry · 2026Article
- The relationship between negative life events and anhedonia among patients with major depressive disorder: chain mediation of insomnia and dysfunctional attitudes.BMC psychiatry · 2026Article
- Anhedonia and altered reward responsiveness: Relations to psychosocial functioning.Journal of mood and anxiety disorders · 2026Article
- Parsing Reward Processing Substages With Multimodal EEG-fMRI.Human brain mapping · 2026Article
- Basal Ganglia Dopamine Availability and Immune Activation Interact and Relate to Anhedonia Severity among Youth with Depression.Research square · 2026Article
- Sphingolipids in Emotional Well-Being.Journal of neurochemistry · 2026Review
- From Neural Circuits to Behavior: Examining the Central Role of Anhedonia in Major Depression.Advances in experimental medicine and biology · 2026Review
- Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.Neuropsychiatric disease and treatment · 2026Article
- Neonatal striatal volume is associated with infant anhedonia.Journal of affective disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Leading professional health bodies have called for the wider adoption of Patient Reported Outcome Measures, such as quality of life, in research and clinical practice as a means for understanding why the global burden of depression continues to climb despite increased rates of treatment use. Here, we examined whether anhedonia-an often recalcitrant and impairing symptom of depression-along with its neural correlates, was associated with longitudinal changes in patient-reported quality of life among individuals seeking treatment for mood disorders. We recruited 112 participants, including n = 80 individuals with mood disorders (58 unipolar, 22 bipolar) and n = 32 healthy controls (63.4% female). We assessed anhedonia severity along with two electroencephalographic markers of neural reward responsiveness (scalp-level 'Reward Positivity' amplitude and source-localized reward-related activation in the dorsal anterior cingulate cortex), and assessed quality of life at baseline, 3- and 6-month follow-up. Anhedonia emerged as a robust correlate of quality of life cross-sectionally and longitudinally among individuals with mood disorders. Furthermore, increased neural reward responsiveness at baseline was associated with greater improvements in quality of life over time, and this improvement was mediated by longitudinal improvements in anhedonia severity. Finally, differences in quality of life observed between individuals with unipolar and bipolar mood disorders were mediated by differences in anhedonia severity. Our findings indicate that anhedonia and its reward-related neural correlates are linked to variability in quality of life over time in individuals with mood disorders. Treatments capable of improving anhedonia and normalizing brain reward function may be necessary for improving broader health outcomes for individuals seeking treatment for depression.ClinicalTrials.gov identifier: NCT01976975.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.